Click on headlines below to download research

Phase IIb/III mesdopetam study expanded
IRLAB Therapeutics | 14/07/2022

IRLAB Therapeutics, alongside partner Ipsen, has announced an expansion of the Phase IIb/III study of mesdopetam in patients with levodopa-induced dyskinesias…

Clinical pipeline is tip of the iceberg
IRLAB Therapeutics | 23/06/2022

While clinical results from the mesdopetam (Phase IIb) and pirepemat (Phase IIb) trials are the near-term value drivers for IRLAB, in our view a growing…

Richard Godfrey appointed as new CEO
IRLAB Therapeutics | 14/06/2022

IRLAB Therapeutics has announced the appointment of Richard Godfrey as its new CEO, replacing Nicholas Waters. The new management structure will see Richard…